Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

Stock Information for Niagen Bioscience Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Niagen Bioscience Inc.

Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR - West 2026 Meeting
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.